Status:

COMPLETED

Tenecteplase Reperfusion Therapy in Acute Ischaemic Cerebrovascular Events-5

Lead Sponsor:

Beijing Tiantan Hospital

Conditions:

Ischemic Stroke, Acute

Eligibility:

All Genders

18+ years

Phase:

PHASE3

Brief Summary

The trial is a multicentre, prospective, open-label, blinded endpoint (PROBE), phase 3, randomized controlled design. Patients with acute ischemic stroke due to basilar artery occlusion presenting wit...

Detailed Description

The study will be a multicentre, prospective, open-label, blinded endpoint (PROBE), randomized controlled trial (2 arm with 1:1 randomization) in patients with acute ischemic stroke due to basilar art...

Eligibility Criteria

Inclusion

  • Age ≥18.
  • Patients presenting with posterior circulation ischemic stroke symptoms due to near-complete or complete basilar artery occlusion within 24 hours from symptom onset (or clinical deterioration/coma) or the time the patient was last known to be well.
  • Presence of a basilar artery occlusion, proven by CT Angiography or MR Angiography. Basilar artery occlusion will be defined as 'potentially retrievable' occlusion at the basilar artery. This can be a near or complete occlusion.
  • Premorbid mRS ≤3 (independent function or requiring only minor domestic assistance and able to manage alone for at least 1 week).
  • Local legal requirements for consent have been satisfied.

Exclusion

  • Intracerebral haemorrhage (ICH) or other diagnosis (e.g. tumour) identified by baseline imaging.
  • Posterior circulation Acute Stroke Prognosis Early CT Score (PC-ASPECTS) \<6 on non-contrast CT (NCCT) or CTA-source images or MRI diffusion weighted imaging (DWI).
  • Significant cerebellar mass effect or acute hydrocephalus.
  • Established frank hypodensity on non-contrast CT indicating subacute infarction.
  • Bilateral extensive brainstem ischemia.
  • Pre-stroke mRS of ≥4 (indicating moderate to severe previous disability).
  • Other standard contraindications to intravenous thrombolysis.
  • Contraindication to imaging with contrast agents.
  • Clinically evident pregnant women.
  • Vessel imaging showing both anterior and posterior circulation large vessel occlusion.
  • Current participation in another research drug treatment protocol.
  • Known terminal illness such that the patients would not be expected to survive a year.
  • Planned withdrawal of care or comfort care measures.
  • Any condition that, in the judgment of the investigator could impose hazards to the patient if study therapy is initiated or affect the participation of the patient in the study.

Key Trial Info

Start Date :

January 24 2024

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

September 22 2025

Estimated Enrollment :

452 Patients enrolled

Trial Details

Trial ID

NCT06196320

Start Date

January 24 2024

End Date

September 22 2025

Last Update

November 26 2025

Active Locations (59)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 15 (59 locations)

1

Taihe County Traditional Chinese Medicine Hospital

Fuyang, Anhui, China

2

Lixin County People's Hospital

Haozhou, Anhui, China

3

Beijing Tian Tan Hospital, Capital Medical University

Beijing, Beijing Municipality, China, 100070

4

First People's Hospital of Tianshui

Tianshui, Gansu, China